Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Advanced Urothelial Cancer
NCT00066352Phase 2Completed
- Sponsor
- University Health Network
- Start
- Sep 2003
- Primary completion
- Sep 2003
- Modality
- Small Molecules, Modified Peptides
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in urothelial carcinoma (UC), sponsored by University Health Network. Primary endpoint: Objective Response Rate. Started Sep 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT00066352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00066352.